RxDoctor Payments Data

Ramon Perez, PA

Physician Assistant · Sunnyside, WANPI 1205318946

Payments from drug & device makers

$1,310in general payments, 2019–2025

Across 63 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$285
  • AbbVie$139
  • Pfizer$126
  • Boehringer Ingelheim$114
  • Sanofi-aventis U.S. LLC$84
  • Lilly USA, LLC$74
  • plus $487 from 17 others

What the payments were for

  • Food & beverage$1,310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,310 in reported general payments places this provider in the 85th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$929
Medicare patients
42
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$65,363
JanuviaSitagliptin Phosphate48$52,353
JardianceEmpagliflozin51$43,344
TrulicityDulaglutide29$34,921
FarxigaDapagliflozin Propanediol43$32,650
EliquisApixaban23$22,153
XareltoRivaroxaban14$7,603
Praluent PenAlirocumab13$6,595
Tresiba Flextouch U-100Insulin Degludec11$4,553
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,578
Atorvastatin Calcium186$1,932
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,424
Lisinopril154$1,228
Tamsulosin Hcl74$1,145
Venlafaxine Hcl ErVenlafaxine Hcl11$1,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$65,36364 claims
Boehringer IngelheimJardiance$114$43,34451 claims
Lilly USA, LLCTrulicity$74$34,92129 claims
AstraZenecaFarxiga$285$32,65043 claims
PfizerEliquis$126$22,15323 claims
Johnson & JohnsonXarelto$43$7,60314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Sunnyside

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →